Kymera Therapeutics, Inc. has entered into an underwriting agreement to sell 2,002,313 shares of common stock at $40.75 each and pre-funded warrants for 3,519,159 shares, aiming to raise approximately $246.5 million to fund its clinical programs and general corporate purposes.